Skip to content

Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids

Study of the Expression of Angiotensin-converting Enzyme 2 (ACE2), a Cell Membrane Receptor for SARS-CoV-2 and the TMPRSS2 Serine Protease in Tonsils and Adenoids of Children and Adults

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04640610
Acronym
ACE2-AVG
Enrollment
0
Registered
2020-11-23
Start date
2021-06-30
Completion date
2021-06-30
Last updated
2026-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoidectomy, Tonsillectomy

Keywords

SARS-CoV-2, Angiotensin-converting enzyme 2 (ACE2), Transmembrane serine protease 2 (TMPRSS2), Tonsils, Adenoids

Brief summary

The objective of the research is to study the expression of the ACE 2 receptor and the TMPRSS2 serine protease in the tonsils and adenoids of children and adults.

Detailed description

The entry point for SARS-CoV-2 into the body is the nasal and pharyngeal mucosa. Angiotensin-converting enzyme 2 (ACE 2) was quickly identified as the functional receptor for SARS-CoV-2. Furthermore, the TMPRSS2 serine protease is required for the anchoring of the S protein in cell lines. In addition, the most commonly used screening test is a test for viral RNA by RT-PCR on a nasopharyngeal sample because the viral load is high. The tonsils and adenoids could be a target organ of the virus. In order to study this hypothesis, the expression of ACE 2 and the serine protease TMPRSS2 will be sought in these tissues. In addition, children, generally at high risk of severe viral respiratory infections (RSV, influenza), have milder symptoms than older patients with SARS-CoV-2 infection. The reason for this difference remains elusive. But one of the hypotheses formulated is that the level of expression of ACE 2 and / or TMPRSS2 may differ between adults and children, the viral load seeming to be correlated with the severity of the attack. In order to study this hypothesis, we will therefore compare the level of expression of ACE 2 in the tonsil tissue of children and adults.

Interventions

OTHERStorage of operating waste

Storage of operating waste of adenoidectomy / tonsillectomy

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the hospitals of Assistance Publique-Hôpitaux de Paris participating in the study. * Holders of parental authority of minor patients and adult patients not opposed to participation in the study.

Exclusion criteria

\- N/A

Design outcomes

Primary

MeasureTime frameDescription
Expression of ACE 2 receptor and TMPRSS2 serine protease9 monthsMeasurement of expression of ACE 2 receptor and TMPRSS2 serine protease in tonsils and adenoids labeled by immunofluorescence.

Secondary

MeasureTime frameDescription
Location of ACE 2 receptor and TMPRSS2 serine protease9 monthsLocation of ACE 2 receptor and TMPRSS2 serine protease in tonsils and adenoids labeled by immunofluorescence.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORRomain Luscan, MD

Assistance Publique - Hôpitaux de Paris

STUDY_DIRECTORPierre-Louis Tharaux, MD, PhD

Institut National de la Santé Et de la Recherche Médicale, France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026